What is the difference between the IPSS and the IPSS-R?

(4:2)

Comparing the IPSS-M and IPSS-R for risk stratification of patients with MDS \u0026 spliceosome mutations

(1:30)

Debate: How should IPSS-R intermediate risk MDS be approached? - As higher risk disease

(12:46)

Evaluating IPSS-R and IPSS-M in patients with HR-MDS enrolled in STIMULUS-MDS1 and STIMULUS-MDS2

(1:45)

Relevance of IPSS-R for risk stratification in patients with MDS who undergo SCT

(6:4)

Relevance of the IPSS-R during SCT in patients with MDS in the molecular classification era

(3:31)

Can IPSS-R be used as a prognostic tool in HSCT in regions where molecular analysis is unavailable?

(13:13)

(R-IPSS) Revised International Prognostic Scoring System for MDS

(41)

What is the prognostic classification of MDS?

(2:15)

What is the prognosis for MDS-related anemia? How is prognosis determined?

(1:39)

Prognosis in Myelodysplastic syndromes - using the IPSS (Advanced)

(15:58)

What factors should we consider for intermediate- and high-risk patients beyond the IPSS-R score?

(36:27)

6-Molecular prognostic scoring (IPSS-M) – How does it improve patient management?

(16:7)

Real-world validation of the value of the IPSS-M for prognostication in patients with MDS

(3:35)

How is MDS classified?

(3:16)

How Is Molecular Testing Used in MDS Risk Stratification?

(2:51)

Revised IPSS Score for MDS prognosis

(41)

Risk Stratification in MDS

(7:34)

How Do Prognostic Models Factor into Treatment Decision Making for MDS?

(10:51)